What Researchers Did
The researchers updated an earlier review by searching for new studies, published between 1 February 2021 and 1 April 2022, on hyperbaric oxygen treatment (HBOT) for COVID-19 patients with low blood oxygen.
What They Found
This living systematic review update found that all eight included studies, covering 224 patients, reported improved clinical outcomes with HBOT and no serious adverse events. Two new studies were added, both randomised controlled trials, enrolling 127 patients. One of these had a moderate risk of bias and one had a high risk of bias. Across the eight studies, 114 patients received HBOT. The authors did not combine the results in a meta-analysis because the studies differed too much and reported their data incompletely.
What This Means for Canadian Patients
The review looked only at people with acute COVID-19 and low blood oxygen. For them, the authors concluded that the studies give further evidence on the safety and effectiveness of HBOT. Because the results could not be pooled and two of the newest trials carried moderate or high risk of bias, patients should read this as an early picture and discuss any treatment decision with their own doctor.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The studies varied widely and reported incompletely, so the results could not be pooled, and the two newest trials had a moderate or high risk of bias.